ENTADFI Drug Patent Profile

Which patents cover Entadfi, and when can generic versions of Entadfi launch?

Entadfi is a drug marketed by Blue Water Biotech and is included in one NDA.

The generic ingredient in ENTADFI is finasteride; tadalafil. There is one drug master file entry for this compound. Additional details are available on the finasteride; tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Entadfi

A generic version of ENTADFI was approved as finasteride; tadalafil by NOVITIUM PHARMA on March 19^th, 2025.

Summary for ENTADFI

US Patents:	0
Applicants:	1
NDAs:	1
Drug Prices:	Drug price information for ENTADFI
What excipients (inactive ingredients) are in ENTADFI?	ENTADFI excipients list
DailyMed Link:	ENTADFI at DailyMed

See drug prices for ENTADFI

US Patents and Regulatory Information for ENTADFI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Blue Water Biotech	ENTADFI	finasteride; tadalafil	CAPSULE;ORAL	215423-001	Dec 9, 2021		DISCN	Yes	No

ENTADFI Market Dynamics, Patent Outlook, and Financial Trajectory

Last updated: September 14, 2026

ENTADFI is a fixed-dose combination of tadalafil 5 mg and finasteride 5 mg for the initial treatment of signs and symptoms of benign prostatic hyperplasia, or BPH, in men with an enlarged prostate. Veru Inc. received FDA approval in December 2021. The product has a clinically understandable value proposition, but its commercial position is constrained by low-cost generic alternatives, limited treatment duration in the approved indication, reimbursement friction, and the absence of separately reported product revenue.

ENTADFI’s commercial opportunity is therefore more likely to remain a niche branded combination opportunity than become a large primary-care product. Its long-dated formulation patent may delay direct fixed-dose generic competition, but it does not prevent physicians from prescribing tadalafil and finasteride as separate generic products.

What is ENTADFI and what FDA indication does it have?

ENTADFI combines two established BPH therapies:

Attribute	ENTADFI
Active ingredients	Tadalafil 5 mg and finasteride 5 mg
Dosage form	Oral capsule
Sponsor	Veru Inc.
FDA application	NDA 214694
FDA approval	December 2021
Indication	Initial treatment of BPH signs and symptoms in men with an enlarged prostate
Dosing	One capsule daily
Approved treatment duration	Up to 26 weeks
Product category	Fixed-dose combination drug
Regulatory status	FDA-approved prescription product

The product combines tadalafil’s smooth-muscle relaxation effect with finasteride’s reduction of prostate dihydrotestosterone activity. Tadalafil can improve urinary symptoms relatively quickly, while finasteride is intended to reduce prostate size over time.

The FDA label limits ENTADFI to initiation of therapy for up to 26 weeks. The label does not establish ENTADFI as a permanent replacement for separate long-term maintenance therapy with tadalafil, finasteride, or another BPH regimen (U.S. Food and Drug Administration, 2021).

How large is the market for ENTADFI?

The addressable market is large in patient count but difficult to monetize with a premium fixed-dose product.

BPH is common among older men, and treatment spans alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, combination regimens, and minimally invasive procedures. Tamsulosin, finasteride, dutasteride, and generic tadalafil are widely available at low prices.

ENTADFI competes primarily against these treatment options:

Competitor or substitute	Main advantage	Commercial constraint for ENTADFI
Generic tadalafil 5 mg	Same PDE-5 inhibitor component at low cost	Can be prescribed separately
Generic finasteride 5 mg	Low-cost long-term prostate therapy	Can be prescribed separately
Tadalafil plus finasteride prescribed separately	Therapeutically similar two-drug regimen	Avoids branded fixed-dose premium
Tamsulosin	Established first-line BPH therapy	Strong generic familiarity
Dutasteride	Established prostate-shrinking therapy	Generic competition
Tamsulosin plus dutasteride combinations	Familiar combination approach	Established clinical use
Daily tadalafil monotherapy	Covers BPH symptoms and erectile dysfunction	No finasteride exposure
BPH procedures	Durable symptom relief for selected patients	Procedure risk and cost

ENTADFI’s strongest commercial use case is a patient who needs both tadalafil and finasteride, prefers one capsule, and has insurance coverage that does not create a material copay disadvantage. The product is less compelling when the same ingredients can be obtained separately for a fraction of the cost.

What is the commercial differentiation of ENTADFI?

ENTADFI’s differentiation is convenience rather than a new pharmacologic mechanism. The product offers:

1. A single daily capsule.
2. Simultaneous initiation of tadalafil and finasteride.
3. A branded option for patients who may also value tadalafil’s erectile-dysfunction benefits.
4. A treatment pathway that avoids separate prescriptions and separate pharmacy fills.

The commercial weakness is that fixed-dose convenience is easy for competitors to replicate through separate generic prescriptions. Physicians can prescribe tadalafil 5 mg and finasteride 5 mg together without using ENTADFI.

ENTADFI also has a narrower positioning than a conventional long-term BPH product because the FDA indication is for initial treatment for up to 26 weeks. After that period, a patient may transition to generic components or another therapy. This reduces recurring branded exposure unless the prescriber continues the product outside the label or restarts it in another treatment context.

What patents protect ENTADFI?

ENTADFI’s principal U.S. protection is associated with a formulation patent covering the combination of tadalafil and finasteride.

Patent	Subject matter	Listed assignee	Expected patent-term endpoint
U.S. Patent No. 11,096,918	Pharmaceutical composition combining tadalafil and finasteride for BPH treatment	Veru Inc.	March 2038, subject to statutory adjustments and applicable regulatory extensions

The patent provides a potential barrier to an identical fixed-dose capsule. It does not prevent:

• Separate generic tadalafil and finasteride prescriptions.
• Use of tadalafil or finasteride individually.
• Alternative BPH combinations.
• Potentially non-infringing formulations or dosage presentations.
• Compounded products, subject to applicable federal and state requirements.

The commercial value of the patent is therefore narrower than the headline expiration date suggests. The protected product is the branded combination, while the underlying active ingredients are mature and widely genericized.

What is the Orange Book status of ENTADFI?

ENTADFI is an FDA-approved drug listed in the Orange Book under its NDA. The Orange Book identifies the patent information submitted by the sponsor and provides the framework for abbreviated new drug application, or ANDA, applicants to make patent certifications.

The key regulatory issue is whether the listed patent creates a practical barrier to an ANDA for the same dosage form and strength. A generic applicant seeking approval before patent expiration would generally need to address the listed patent through a Paragraph IV certification or wait for patent expiration.

ENTADFI does not receive the same market protection as a new chemical entity because tadalafil and finasteride were previously approved active ingredients. Its commercial protection depends more heavily on the fixed-dose formulation patent and any applicable regulatory exclusivity.

When does ENTADFI lose exclusivity?

ENTADFI’s principal exclusivity milestones are:

Protection type	Approximate endpoint	Business effect
FDA approval	December 2021	Product became commercially eligible
Potential three-year new-drug exclusivity for a new combination	December 2024	May restrict certain ANDAs relying on qualifying clinical investigations
Listed formulation patent	March 2038	May delay an identical fixed-dose generic
Underlying tadalafil and finasteride molecule patents	Expired or substantially expired	Do not protect ENTADFI’s active ingredients

The three-year exclusivity analysis depends on the FDA’s determination of qualifying new clinical investigations and the precise ANDA pathway. It is materially less important than the formulation patent after 2024.

The patent expiration date is also not an absolute generic-entry date. A generic may enter earlier through a successful Paragraph IV challenge, a settlement agreement, a finding of non-infringement or invalidity, or a negotiated license.

Which companies are challenging ENTADFI’s patent estate?

No major publicly established Paragraph IV litigation campaign against ENTADFI is central to the product’s current commercial profile. Publicly visible market pressure has instead come from generic substitution at the ingredient level.

Potential ANDA applicants include large generic manufacturers such as Teva, Viatris, Sandoz, Dr. Reddy’s Laboratories, Lupin, Zydus, and other companies active in tadalafil, finasteride, or combination products. An ANDA applicant could challenge the formulation patent, design around the claimed composition, or wait for patent expiry.

The absence of a prominent challenge does not eliminate generic risk. ENTADFI’s low current sales base may reduce the incentive for a large generic company to incur litigation expense before the commercial market has been proven.

How strong is the ENTADFI patent estate?

ENTADFI has a potentially long patent term but a commercially narrow patent moat.

Strengths

• The patent may remain in force until 2038.
• A direct substitute with the same fixed-dose formulation could face infringement risk.
• The product addresses a recognized convenience problem in BPH prescribing.
• A patent covering the combination may be more durable than patents covering only the individual molecules.

Weaknesses

• Tadalafil and finasteride are both mature generic ingredients.
• Separate-pill substitution is straightforward.
• The product’s clinical differentiation is limited.
• The approved treatment duration is capped at 26 weeks.
• A generic applicant may challenge validity, claim construction, or infringement.
• Physicians can achieve the same two-drug pharmacologic regimen without the branded capsule.

The estate is stronger against an identical fixed-dose generic than against therapeutic substitution. Its economic value depends on whether Veru can create sufficient branded demand and reimbursement support before a challenger invests in litigation or a design-around product.

What has been ENTADFI’s financial trajectory?

Veru does not report ENTADFI revenue as a large, separately disclosed operating segment in its public financial statements. Company reporting has historically been dominated by other activities, including the FC2 female condom business and the company’s clinical-stage pharmaceutical programs. As a result, ENTADFI-specific revenue, gross margin, prescription volume, and customer acquisition cost are not publicly transparent at the level required for a conventional branded-drug valuation.

The observable financial trajectory has several characteristics:

Financial factor	Effect on ENTADFI
Separate product revenue disclosure	Limited or absent in public company reporting
Commercial scale	Appears modest relative to Veru’s total business
Cost of goods	Likely manageable because the active ingredients are established
Selling expense	Can be significant relative to sales for a niche branded product
Reimbursement	Central determinant of net price and persistence
Generic substitution	Creates strong pressure on price
Patient duration	Limited by the 26-week FDA indication
Cash-flow contribution	Unlikely to be a primary driver of Veru’s financial profile

The main financial risk is not manufacturing complexity. It is the cost of generating prescriptions for a product that competes with inexpensive generic components. A branded combination needs either a meaningful price premium supported by reimbursement or a large enough patient base to spread selling and marketing costs.

What licensing deals affect ENTADFI?

No major publicly disclosed third-party licensing transaction is a central element of ENTADFI’s commercial history. Veru appears to retain the principal product rights and regulatory responsibility.

The lack of a major licensing partner has two implications:

• Veru retains more control over pricing, promotion, and commercialization.
• Veru also bears the cost of building physician awareness, payer access, and pharmacy distribution.

A licensing or co-promotion agreement with a company that has an established urology sales force could improve reach, but it would reduce Veru’s economics through royalties, milestones, profit sharing, or transfer pricing.

What generic launch scenarios exist for ENTADFI?

Three generic-entry scenarios are commercially relevant.

Early Paragraph IV entry

A generic applicant challenges the listed patent and wins, settles for an agreed entry date, or obtains a court ruling that the claims are invalid or not infringed. This would create the fastest erosion scenario.

Patent-protected branded window

The patent remains enforceable, and no applicant launches before expiry. ENTADFI maintains exclusivity against an identical fixed-dose generic through the patent term, but separate generic prescriptions continue to limit pricing.

Post-expiry fixed-dose competition

One or more ANDA products enter after patent expiry. ENTADFI would then face direct price competition in addition to the existing two-pill substitute.

The highest-probability commercial threat is therapeutic substitution rather than immediate direct generic launch. Generic tadalafil and finasteride already provide an effective alternative without waiting for ENTADFI’s patent to expire.

How does ENTADFI compare with other BPH therapies?

ENTADFI is differentiated by convenience but disadvantaged by price and duration.

Product strategy	Symptom relief	Prostate-size effect	Erectile-function benefit	Generic pressure
ENTADFI	Tadalafil component	Finasteride component	Yes	High through separate generics
Tadalafil alone	Yes	No meaningful prostate shrinkage	Yes	Very high
Finasteride alone	Slower	Yes	No	Very high
Tamsulosin	Relatively rapid	No	No	Very high
Tadalafil plus finasteride separately	Yes	Yes	Yes	Very high
Dutasteride-based regimen	Slower	Yes	No	High

ENTADFI’s best competitive position is among patients for whom convenience and dual-mechanism treatment outweigh the cost of separate generic therapy. Its weakest position is in price-sensitive formularies and cash-pay channels.

What revenue exposure does ENTADFI create for Veru?

ENTADFI is unlikely to represent a major concentration risk to Veru’s consolidated revenue unless product sales increase materially. The more important exposure is strategic: commercial resources allocated to ENTADFI may produce limited returns if prescription volume remains low.

For investors and potential partners, the key metrics are:

• Net sales by quarter.
• New and total prescriptions.
• Average revenue per prescription.
• Payer rejection and prior-authorization rates.
• Cash-pay versus insured volume.
• Marketing expense per new patient.
• Refill persistence beyond the initial treatment period.
• Gross-to-net deductions.
• Product contribution margin.
• Any settlement or license involving the listed patent.

Because ENTADFI-specific metrics are not prominently disclosed, external valuation should not assign blockbuster economics based on the size of the BPH patient population alone.

What is the regulatory and geographic outlook?

ENTADFI has U.S. FDA approval. U.S. market performance is the primary visible commercial reference point. Foreign commercialization would require country-specific regulatory approvals, pricing decisions, reimbursement negotiations, and potentially new patent enforcement strategies.

Geographic expansion faces the same basic problem in every market: tadalafil and finasteride are established products, and many countries use generic substitution aggressively. The combination may have value in markets where fixed-dose products receive favorable reimbursement, but a global rollout would require evidence that convenience can support a premium over separate generics.

Key Takeaways

• ENTADFI is a branded fixed-dose combination of tadalafil 5 mg and finasteride 5 mg for initial BPH treatment.
• FDA approval came in December 2021 under NDA 214694.
• The label limits the approved initial-treatment course to 26 weeks.
• The commercial opportunity is large in patient count but constrained by cheap generic alternatives.
• The principal U.S. formulation patent is expected to run to March 2038, subject to statutory adjustments.
• Patent protection blocks an identical fixed-dose generic more effectively than it blocks separate generic tadalafil and finasteride prescribing.
• ENTADFI-specific financial disclosure is limited, and the product does not appear to be a primary driver of Veru’s consolidated financial profile.
• No major public Paragraph IV litigation campaign is central to the product’s market position.
• The principal risk is therapeutic substitution, not manufacturing difficulty.
• Commercial success depends on reimbursement, prescriber adoption, patient convenience, and marketing efficiency.

FAQs

Is ENTADFI a generic drug?

No. ENTADFI is a branded FDA-approved fixed-dose combination product marketed by Veru. Its active ingredients, tadalafil and finasteride, are available separately as generic drugs.

Can a patient take generic tadalafil and finasteride instead of ENTADFI?

Physicians can prescribe tadalafil and finasteride separately when clinically appropriate. That substitution is the main economic challenge to ENTADFI because it may provide similar pharmacologic coverage at a lower cost.

Does ENTADFI treat erectile dysfunction?

ENTADFI contains tadalafil, a drug also used for erectile dysfunction. Its FDA-approved indication is the treatment of BPH signs and symptoms in men with an enlarged prostate, not a standalone erectile-dysfunction indication.

Will a generic version of ENTADFI launch before 2038?

A direct generic could launch before the expected patent endpoint if an ANDA applicant successfully challenges the listed patent, reaches a settlement allowing early entry, or develops a non-infringing product. Separate generic tadalafil and finasteride are already available.

Is ENTADFI commercially important to Veru?

ENTADFI is a commercial product, but public filings do not establish it as a major contributor to Veru’s consolidated revenue. Its financial importance depends on whether prescription growth can overcome generic price competition and limited branded treatment duration.

References

1. U.S. Food and Drug Administration. (2021). ENTADFI (tadalafil and finasteride) prescribing information. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

3. U.S. Patent and Trademark Office. (2021). U.S. Patent No. 11,096,918: Pharmaceutical composition for treatment of benign prostatic hyperplasia. U.S. Department of Commerce.

4. Veru Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Enlarged prostate: Benign prostatic hyperplasia. National Institutes of Health.

DrugChatter Q&A for ENTADFI

Entadfi discount?